SanegeneBio Announces FDA Orphan Drug Designation for SGB-9768 for the Treatment of IC-MPGN

BOSTON, SHANGHAI, and SUZHOU – February 24, 2026, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, announced that SGB-9768 has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN). IC-MPGN is a rare kidney disease primarily caused by overactivation of the […] The post SanegeneBio Announces FDA Orphan Drug Designation for SGB-9768 for the Treatment of IC-MPGN appeared first on SanegeneBio .